BCL-2 Inhibition in MDS
- 1 September 2021
- journal article
- abstracts
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21, S104-S106
- https://doi.org/10.1016/s2152-2650(21)01228-3
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaThe New England Journal of Medicine, 2020
- Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failureBlood Advances, 2020
- Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored doseExperimental Hematology & Oncology, 2019
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Apoptosis, bcl-2 Expression and p53 Accumulation in Myelodysplastic Syndrome, Myelodysplastic-Syndrome-Derived Acute Myelogenous Leukemia and de novo Acute Myelogenous LeukemiaActa Haematologica, 1999